Next Article in Journal
Trends in Tuberculosis Incidence in the Australian-Born in Victoria: Opportunities and Challenges to Elimination
Next Article in Special Issue
Potential Impact of Climate Change on Schistosomiasis: A Global Assessment Attempt
Previous Article in Journal
Zoonotic Helminth Diseases in Dogs and Dingoes Utilising Shared Resources in an Australian Aboriginal Community
Previous Article in Special Issue
“Farewell to the God of Plague”: The Importance of Political Commitment Towards the Elimination of Schistosomiasis
Open AccessArticle

Low Praziquantel Treatment Coverage for Schistosoma mansoni in Mayuge District, Uganda, Due to the Absence of Treatment Opportunities, Rather Than Systematic Non-Compliance

1
Vector Control Division, Ministry of Health, Plot 15 Bombo Road, P.O. Box 1661, Kampala, Uganda
2
Institute of Biodiversity, Animal Health and Comparative Medicine and Wellcome Centre for Molecular Parasitology, University of Glasgow, Glasgow G12 8QQ, UK
*
Authors to whom correspondence should be addressed.
Joint first authors, listed in alphabetical order.
Trop. Med. Infect. Dis. 2018, 3(4), 111; https://doi.org/10.3390/tropicalmed3040111
Received: 5 September 2018 / Revised: 25 September 2018 / Accepted: 26 September 2018 / Published: 8 October 2018
(This article belongs to the Special Issue Prospects for Schistosomiasis Elimination)
The World Health Organization (WHO) recommends praziquantel mass drug administration (MDA) to control schistosomiasis in endemic regions. We aimed to quantify recent and lifetime praziquantel coverage, and reasons for non-treatment, at an individual level to guide policy recommendations to help Uganda reach WHO goals. Cross-sectional household surveys (n = 681) encompassing 3208 individuals (adults and children) were conducted in 2017 in Bugoto A and B, Mayuge District, Uganda. Participants were asked if they had received praziquantel during the recent MDA (October 2016) and whether they had ever received praziquantel in their lifetime. A multivariate logistic regression analysis with socio-economic and individual characteristics as covariates was used to determine factors associated with praziquantel uptake. In the MDA eligible population (≥5 years of age), the most recent MDA coverage was 48.8%. Across individuals’ lifetimes, 31.8% of eligible and 49.5% of the entire population reported having never taken praziquantel. Factors that improved individuals’ odds of taking praziquantel included school enrolment, residence in Bugoto B and increasing years of village-residency. Not being offered (49.2%) and being away during treatment (21.4%) were the most frequent reasons for not taking the 2016 praziquantel MDA. Contrary to expectations, chronically-untreated individuals were rarely systematic non-compliers, but more commonly not offered treatment. View Full-Text
Keywords: Mayuge; MDA coverage; praziquantel; S. mansoni; systematic non-compliance; treatment-opportunities; Uganda Mayuge; MDA coverage; praziquantel; S. mansoni; systematic non-compliance; treatment-opportunities; Uganda
Show Figures

Figure 1

MDPI and ACS Style

Adriko, M.; Faust, C.L.; Carruthers, L.V.; Moses, A.; Tukahebwa, E.M.; Lamberton, P.H.L. Low Praziquantel Treatment Coverage for Schistosoma mansoni in Mayuge District, Uganda, Due to the Absence of Treatment Opportunities, Rather Than Systematic Non-Compliance. Trop. Med. Infect. Dis. 2018, 3, 111.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop